Compare Natera Inc. Common Stock (NTRA) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Snap On Incorporated — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Snap On Incorporated trades at $365.17 (market cap $18.80B). The key difference: Natera Inc. Common Stock is far larger — about 3× Snap On Incorporated's market cap, and Snap On Incorporated pays a 2.68% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Snap On Incorporated for 38 Days on average.
| NTRA | SNA | |
|---|---|---|
Market Cap | $57.03B | $18.80B |
Volume | 1,131,157 | 214,829 |
Sector | Health | Industrials |
52-Week High | $425.64 | $419.31 |
52-Week Low | $179.42 | $328.69 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $56.18B | $18.44B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Snap-On Incorporated (SNA) trades at $363.67, up 0.46% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 19.6% net income margin and a 17.58% ROE. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 2026 missing. Analyst consensus is bullish with a $449 price target, though technical indicators suggest near-term caution amid institutional positioning shifts.
The outlook for SNA is supported by solid fundamentals and analyst optimism, but faces headwinds from technical bearishness and valuation risks. Upside potential exists if earnings momentum continues, while risks include execution challenges and market volatility. The stock's premium valuation requires sustained growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
